Baidu
map

Pediatr Dermatol:儿童中血清羟基维生素D与过敏性皮肤炎相关性分析

2020-02-23 AlexYang MedSci原创

之前的研究将低水平血清维生素D(VD)或者25-羟基维生素D(25(OH)D)水平与儿童过敏性皮肤炎严重度的增加联系了起来。最近,有研究人员调查了血清VD(25(OH)D)水平和AD以及AD严重度之间的相关性,并考虑了饮食和太阳照射的影响。研究是一个具有前瞻性的代表研究,包括了健康儿童和诊断为AD的儿童。参与者在2011年1月和2012年12月之间被招募,并评估了年龄、性别、身体质量指数(BMI)

之前的研究将低水平血清维生素D(VD)或者25-羟基维生素D(25(OH)D)水平与儿童过敏性皮肤炎严重度的增加联系了起来。最近,有研究人员调查了血清VD(25(OH)D)水平和AD以及AD严重度之间的相关性,并考虑了饮食和太阳照射的影响。

研究是一个具有前瞻性的代表研究,包括了健康儿童诊断为AD的儿童。参与者在2011年1月和2012年12月之间被招募,并评估了年龄、性别、身体质量指数(BMI)、AD严重度、Fitzpatrick皮肤类型、哮喘和鼻炎历史、日常VD摄入、日常阳光诱导的VD产生、防晒霜使用、25(OH)D和lgE水平以及婴儿免疫CAP Phadiatop试验结果。研究包括了105名健康对照和134名AD患者。研究发现,血清25(OH)D水平在中度和中度AD中要比轻度AD显著更低,且该相关性仅仅在轻度Fitzpatrick皮肤类型(均值(SD)36.7 (11.9)ng / mL;中度28.8(11.5)ng/mL;重度27.6(12.1)ng/mL, P=0.045)中显著。逻辑回归分析阐释了重度AD和阳性免疫CAP Phadiatop测试和BMI相关。

最后,研究人员指出,他们的数据支持了VD缺失和AD严重度仅在浅肤色中存在相关性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837798, encodeId=6a68183e798a5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 03 08:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639366, encodeId=7d14163936699, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 16 01:52:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728313, encodeId=5e091e2831382, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jan 28 15:52:00 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047228, encodeId=11b7204e228fb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 30 22:52:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466522, encodeId=2a4c1466522d6, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523640, encodeId=67b01523640a1, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837798, encodeId=6a68183e798a5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 03 08:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639366, encodeId=7d14163936699, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 16 01:52:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728313, encodeId=5e091e2831382, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jan 28 15:52:00 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047228, encodeId=11b7204e228fb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 30 22:52:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466522, encodeId=2a4c1466522d6, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523640, encodeId=67b01523640a1, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837798, encodeId=6a68183e798a5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 03 08:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639366, encodeId=7d14163936699, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 16 01:52:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728313, encodeId=5e091e2831382, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jan 28 15:52:00 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047228, encodeId=11b7204e228fb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 30 22:52:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466522, encodeId=2a4c1466522d6, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523640, encodeId=67b01523640a1, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2021-01-28 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837798, encodeId=6a68183e798a5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 03 08:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639366, encodeId=7d14163936699, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 16 01:52:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728313, encodeId=5e091e2831382, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jan 28 15:52:00 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047228, encodeId=11b7204e228fb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 30 22:52:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466522, encodeId=2a4c1466522d6, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523640, encodeId=67b01523640a1, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837798, encodeId=6a68183e798a5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 03 08:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639366, encodeId=7d14163936699, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 16 01:52:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728313, encodeId=5e091e2831382, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jan 28 15:52:00 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047228, encodeId=11b7204e228fb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 30 22:52:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466522, encodeId=2a4c1466522d6, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523640, encodeId=67b01523640a1, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837798, encodeId=6a68183e798a5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 03 08:52:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639366, encodeId=7d14163936699, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 16 01:52:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728313, encodeId=5e091e2831382, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jan 28 15:52:00 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047228, encodeId=11b7204e228fb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 30 22:52:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466522, encodeId=2a4c1466522d6, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523640, encodeId=67b01523640a1, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Tue Feb 25 02:52:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]

相关资讯

Clin Exp Dermatol:在患有过敏性皮肤炎的中国患者中,芳香烃受体多样性与皮肤干燥相关

表皮屏障功能障碍是过敏性皮肤炎(AD)发展的一个起始事件。最近的研究鉴定了芳香烃受体(AHR)在控制丝聚合蛋白基因表达和其他皮肤屏障蛋白中的关键角色,表明了AHR与AD发病机理之间潜在的相关性。最近,有研究人员调查了AHR基因多样性在AD敏感性和AD相关表型中的作用。研究包括了487名患有AD的患者,210名患有牛皮癣的患者和226名健康对照。研究发现,AHR rs10249788和rs20668

JDA临床实践指南:过敏性皮肤炎的管理

过敏性皮炎(AD)以复发性湿疹和瘙痒为主要症状,从循证医学角度看,当前日本治疗AD主要包括以下3种措施:外用皮质类固醇和他克莫司为主控制炎症,局部应用润肤剂治疗皮肤屏障功能障碍,避免明显的恶化因素,以及心理咨询和日常生活建议。

Baidu
map
Baidu
map
Baidu
map